Phase 1 Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BMS-906024 in Subjects With Advanced Solid Tumors
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of subjects with adverse events as a measure of safety and tolerability.
Weekly assessments until study discontinuation due to disease progression or unacceptable adverse event as well as an assessment 30 day after treatment discontinuation with an average time on study expected to be <1 year.
United States: Food and Drug Administration
|Wayne State University||Detroit, Michigan 48202|
|Local Institution||Austin, Texas|
|Local Institution||Jackson, Mississippi|
|Anthony El-Khoueiry, Md||Los Angeles, California 90033|